| Followers | 258 |
| Posts | 19732 |
| Boards Moderated | 0 |
| Alias Born | 10/03/2004 |
Thursday, August 15, 2013 5:40:06 PM
Met with Dr. Seymour over lunch:
Some bullet points of things we discussed, none of which was not already public discussion from the company and officers:
-New site construction is ahead of schedule and should finish at the least on time. (This meeting was early Monday before this info was confirmed by NNVCbob onsite observations).
-Wants to move Dengue and flu simultaneously and has the money to do it.
-Because Dengue can't be tested through a challenge protocol with patients inoculated with the virus (made sick with Dengue then treated), it may be approved with only small phase 1/2a under orphan drug/breakthrough.
-In the coming months he will be reporting progress for EKC, HSV, HIV studies and general nanoviricide tweaking.
-IMO, the biggest thing, Anil was able to develop the MERS solution in less than a week. Less than a week for the type that will be tested in EU is pretty amazing and beats the 3 weeks of the rapid in field technology they previously talked about.
-Looking for an Aspire type deal for future money needs.
-Now looking to go it alone by a strategy of contract manufacturing and alternative avenues of distribution. At this point, he sees no reason to hand over a nanoviricide license after Anil and crew have done all the work, and that license in return for the smallest percentage. (I think this could change with the right deal, a partnership with 50/50 split and the partner picks up the remaining costs plus pays huge benchmarks. Those deals are out there.)
Some bullet points of things we discussed, none of which was not already public discussion from the company and officers:
-New site construction is ahead of schedule and should finish at the least on time. (This meeting was early Monday before this info was confirmed by NNVCbob onsite observations).
-Wants to move Dengue and flu simultaneously and has the money to do it.
-Because Dengue can't be tested through a challenge protocol with patients inoculated with the virus (made sick with Dengue then treated), it may be approved with only small phase 1/2a under orphan drug/breakthrough.
-In the coming months he will be reporting progress for EKC, HSV, HIV studies and general nanoviricide tweaking.
-IMO, the biggest thing, Anil was able to develop the MERS solution in less than a week. Less than a week for the type that will be tested in EU is pretty amazing and beats the 3 weeks of the rapid in field technology they previously talked about.
-Looking for an Aspire type deal for future money needs.
-Now looking to go it alone by a strategy of contract manufacturing and alternative avenues of distribution. At this point, he sees no reason to hand over a nanoviricide license after Anil and crew have done all the work, and that license in return for the smallest percentage. (I think this could change with the right deal, a partnership with 50/50 split and the partner picks up the remaining costs plus pays huge benchmarks. Those deals are out there.)
Recent NNVC News
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM

